AU2017248253B2 - Silicone atoms containing ivacaftor analogues - Google Patents

Silicone atoms containing ivacaftor analogues Download PDF

Info

Publication number
AU2017248253B2
AU2017248253B2 AU2017248253A AU2017248253A AU2017248253B2 AU 2017248253 B2 AU2017248253 B2 AU 2017248253B2 AU 2017248253 A AU2017248253 A AU 2017248253A AU 2017248253 A AU2017248253 A AU 2017248253A AU 2017248253 B2 AU2017248253 B2 AU 2017248253B2
Authority
AU
Australia
Prior art keywords
compound
disease
tert
cftr
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017248253A
Other languages
English (en)
Other versions
AU2017248253A1 (en
Inventor
Cecilia M. Bastos
Benito Munoz
Daniel Parks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Inc
Original Assignee
Proteostasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteostasis Therapeutics Inc filed Critical Proteostasis Therapeutics Inc
Publication of AU2017248253A1 publication Critical patent/AU2017248253A1/en
Application granted granted Critical
Publication of AU2017248253B2 publication Critical patent/AU2017248253B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017248253A 2016-04-07 2017-04-07 Silicone atoms containing ivacaftor analogues Active AU2017248253B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319439P 2016-04-07 2016-04-07
US62/319,439 2016-04-07
PCT/US2017/026579 WO2017177124A1 (en) 2016-04-07 2017-04-07 Silicone atoms containing ivacaftor analogues

Publications (2)

Publication Number Publication Date
AU2017248253A1 AU2017248253A1 (en) 2018-10-18
AU2017248253B2 true AU2017248253B2 (en) 2021-07-29

Family

ID=58549338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017248253A Active AU2017248253B2 (en) 2016-04-07 2017-04-07 Silicone atoms containing ivacaftor analogues

Country Status (16)

Country Link
US (4) US10662207B2 (enExample)
EP (1) EP3440057B1 (enExample)
JP (1) JP7061076B2 (enExample)
KR (1) KR102448404B1 (enExample)
CN (1) CN109563047A (enExample)
AR (1) AR108203A1 (enExample)
AU (1) AU2017248253B2 (enExample)
BR (1) BR112018070747B1 (enExample)
CA (1) CA3019663C (enExample)
IL (1) IL262030B (enExample)
MA (1) MA43775A (enExample)
MX (1) MX386698B (enExample)
NZ (1) NZ746793A (enExample)
SA (1) SA518400164B1 (enExample)
SG (1) SG11201808682XA (enExample)
WO (1) WO2017177124A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
CA2993450C (en) 2015-07-24 2023-10-24 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
KR20180093882A (ko) 2015-10-06 2018-08-22 프로테오스타시스 테라퓨틱스, 인크. Cftr 조절용 화합물, 조성물, 및 방법
MX386698B (es) 2016-04-07 2025-03-19 Proteostasis Therapeutics Inc Atomos de silicona que contienen analogos de ivacaftor
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
HUE056716T2 (hu) * 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
EP3812379A1 (en) 2016-12-09 2021-04-28 Vertex Pharmaceuticals Incorporated Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2018237174A2 (en) * 2017-06-21 2018-12-27 The Johns Hopkins University Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
AU2018346602B2 (en) * 2017-10-06 2024-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing CFTR activity
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
WO2019195739A1 (en) 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
CN109663129B (zh) * 2019-02-27 2021-05-11 四川大学华西第二医院 扩张型心肌病治疗药物及其应用
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
EP4013741B1 (en) 2019-08-14 2024-04-17 Vertex Pharmaceuticals Incorporated Process of making cftr modulators
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
CN116425642B (zh) * 2023-04-06 2025-06-10 浙江科聚生物医药有限公司 2-甲氧基-4-氟-5-胺基苯酚的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158885A1 (en) * 2011-05-18 2012-11-22 Concert Pharmaceuticals Inc. Deuterated derivatives of ivacaftor
US20140073667A1 (en) * 2011-05-18 2014-03-13 Adam J. Morgan Deuterated cftr potentiators

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812225A1 (de) 1988-04-13 1989-10-26 Basf Ag Isoxazol(isothiazol)-5-carbonsaeureamide
AU6788996A (en) 1995-08-02 1997-02-26 J. Uriach & Cia S.A. New carboxamides with antifungal activity
EP0761654B1 (en) 1995-08-24 2003-06-18 Basf Aktiengesellschaft Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides
DK0957099T3 (da) 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
NZ546365A (en) 2003-10-08 2010-01-29 Vertex Pharma Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
ZA200604578B (en) 2003-11-14 2008-05-28 Vertex Pharma Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
SE0401969D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
US20060100226A1 (en) 2004-09-10 2006-05-11 Sikorski James A 2-Thiopyrimidinones as therapeutic agents
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
JP4822406B2 (ja) 2005-09-26 2011-11-24 ルネサスエレクトロニクス株式会社 表示制御駆動装置および表示システム
WO2007075896A2 (en) 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
KR101394245B1 (ko) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
WO2007086584A1 (ja) 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
WO2008046072A2 (en) 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
BRPI0718162A2 (pt) 2006-10-20 2013-11-26 Irm Llc Composição e métodos para modulara os receptores c-kit e pdgfr
WO2008070739A1 (en) 2006-12-06 2008-06-12 Cytokinetics, Inc. Ksp activators
ES2379746T3 (es) 2007-06-29 2012-05-03 Sk Biopharmaceuticals Co., Ltd. Composición farmacéutica para la prevención y el tratamiento de la restenosis que comprende los derivados del isoxazol
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8211927B2 (en) 2007-08-02 2012-07-03 MSD, Oss B.V. 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
AU2010211114A1 (en) 2009-02-04 2011-06-30 Msd Oss B.V. Isoxazole-5-carboxamide derivatives
CN102421784B (zh) 2009-03-11 2015-09-30 杏林制药株式会社 作为gsk-3抑制剂的7-环烷基氨基喹诺酮
EP2821400B1 (en) * 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US8569899B2 (en) 2009-12-30 2013-10-29 Stmicroelectronics, Inc. Device and method for alignment of vertically stacked wafers and die
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2560650A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
CA2736441A1 (en) 2011-04-06 2012-10-06 The Regents Of The University Of California Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
BR112014001933A2 (pt) 2011-07-29 2017-02-21 Karyopharm Therapeutics Inc moduladores de transporte nuclear e usos dos mesmos
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
PL2814812T3 (pl) 2012-02-16 2017-10-31 Dow Agrosciences Llc Sposób wytwarzania związków sulfiliminowych
UA110436C2 (en) 2012-03-06 2015-12-25 Zoetis Llc Antibacterial phenol compounds
WO2013146970A1 (ja) 2012-03-29 2013-10-03 第一三共株式会社 新規キノリン誘導体
EP2879684B1 (en) 2012-08-01 2019-01-30 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
WO2014045283A1 (en) 2012-09-24 2014-03-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Restoration of the cftr function by splicing modulation
CA2891965A1 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic cftr correctors
WO2014081820A1 (en) 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors
CN109364075B (zh) * 2012-11-21 2021-10-29 顶点制药（欧洲）有限公司 氘化cftr增效剂
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
HK1220610A1 (zh) 2013-03-13 2017-05-12 弗拉特利发现实验室有限责任公司 哒嗪酮化合物和用於治疗囊肿状纤维化的方法
JP6514680B2 (ja) 2013-03-15 2019-05-15 ディスカバリーバイオメッド， インコーポレイテッド クマリン誘導体、ならびに嚢胞性線維症、慢性閉塞性肺疾患、及びミスフォールドタンパク質障害の治療における使用方法
US20160030406A1 (en) 2013-03-15 2016-02-04 Vertex Pharmaceuticals Incorporated Correctors acting through msd1 of cftr protein
US20160074374A1 (en) 2013-04-26 2016-03-17 Vertex Pharmaceuticals Incorporated Correctors acting through msd1 of cftr protein
LU92578B1 (fr) 2013-05-07 2014-12-15 Galapagos Nv Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CA2915975A1 (en) 2013-06-26 2014-12-31 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
WO2015051230A1 (en) 2013-10-04 2015-04-09 Drexel University Novel compositions useful for inhibiting hiv-1 infection and methods using same
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105484A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105477A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US20180147187A1 (en) 2015-01-12 2018-05-31 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2993450C (en) 2015-07-24 2023-10-24 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US20190022071A1 (en) 2015-08-31 2019-01-24 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
KR20180093882A (ko) 2015-10-06 2018-08-22 프로테오스타시스 테라퓨틱스, 인크. Cftr 조절용 화합물, 조성물, 및 방법
AU2016379388A1 (en) 2015-12-22 2018-07-12 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
MX386698B (es) 2016-04-07 2025-03-19 Proteostasis Therapeutics Inc Atomos de silicona que contienen analogos de ivacaftor
CA3023512A1 (en) 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158885A1 (en) * 2011-05-18 2012-11-22 Concert Pharmaceuticals Inc. Deuterated derivatives of ivacaftor
US20140073667A1 (en) * 2011-05-18 2014-03-13 Adam J. Morgan Deuterated cftr potentiators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Showell and Mills, DDT, 2003, Vol 8, No 12, 551-556 *

Also Published As

Publication number Publication date
AU2017248253A1 (en) 2018-10-18
US10662207B2 (en) 2020-05-26
RU2018137683A (ru) 2020-05-12
RU2018137683A3 (enExample) 2020-05-18
NZ746793A (en) 2022-10-28
SA518400164B1 (ar) 2022-05-08
CN109563047A (zh) 2019-04-02
MX386698B (es) 2025-03-19
JP7061076B2 (ja) 2022-04-27
US20240368198A1 (en) 2024-11-07
BR112018070747A2 (pt) 2019-06-18
US11248010B2 (en) 2022-02-15
KR102448404B1 (ko) 2022-09-27
BR112018070747B1 (pt) 2024-01-09
CA3019663A1 (en) 2017-10-12
AR108203A1 (es) 2018-07-25
EP3440057B1 (en) 2021-09-22
US20210061823A1 (en) 2021-03-04
JP2019513741A (ja) 2019-05-30
MA43775A (fr) 2021-05-05
IL262030B (en) 2021-10-31
US20240109922A1 (en) 2024-04-04
EP3440057A1 (en) 2019-02-13
US20190153000A1 (en) 2019-05-23
KR20180132803A (ko) 2018-12-12
SG11201808682XA (en) 2018-11-29
MX2018012331A (es) 2019-05-23
CA3019663C (en) 2024-09-24
WO2017177124A1 (en) 2017-10-12
IL262030A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
AU2017248253B2 (en) Silicone atoms containing ivacaftor analogues
EP3691638B1 (en) Compounds, compositions and methods for increasing cftr activity
US11136313B2 (en) Compounds, compositions, and methods for modulating CFTR
EP3472156B1 (en) Compounds, compositions, and methods for increasing cftr activity
US20190248779A1 (en) Compounds, compositions, and methods for increasing cftr activity
WO2018081381A1 (en) Pyridazine derivatives, compositions and methods for modulating cftr
WO2016105484A1 (en) Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
RU2796112C2 (ru) Кремнийсодержащие аналоги ивакафтора
HK40004165B (en) Silicone atoms containing ivacaftor analogues
HK1258811B (en) Compounds, compositions, and methods for modulating cftr

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)